secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001778922-26-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops
--------------------------------------------------------------------------------

- 97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.
- Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.
- 100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.
- Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.
- Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/0001778922-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/sgp-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer